Thermo Fisher Scientific
New Psychoactive Substances (NPS) represent an increasing and ever evolving threat to public health. Traditional analytical approaches to drugs of abuse testing are unable to respond quickly enough to be able to keep up to date with the continually changing NPS situation and are therefore unsuitable for this purpose. The availability of drug intelligence often combined with drug seizures provides the starting point for a new approach to drugs of abuse testing using HRAM. Screening processes continually evolve as new compounds emerge and can be further refined using data from in vitro metabolism and/or positive findings.
For forensic use only.
Simon is Technical Director of the Laboratory and Managed Services (LMS) division of LGC. He has over 30 years’ experience in drug testing in humans, horses and greyhounds gained initially at the Drug Control and Teaching Centre performing human sport doping control and then HFL (latterly LGC) performing human sport doping control and drug and medication control in racing animals. Through his career, Simon has a proven track record of introducing new technology to advance laboratory capabilities with the most recent introduction being High Resolution Accurate Mass (HRAM) LCMS. More recently, Simon was responsible for the introduction of specialized workplace drug testing at the LGC Fordham site, analysing for anabolic steroids and NPS utilising HRAM LCMS.
* Required field